Aayush Wellness Limited a pioneer in India’s integrated healthcare space, has announced its strategic entry into diagnostic testing, home sample collection, and teleconsultation services. Building on its experience operating primary healthcare centers, the company is expanding its service offerings through a dedicated website and mobile application, designed to make essential health services more accessible, affordable, and patient-friendly—especially for families, seniors, and busy professionals seeking convenient care from home.

New Services at a Glance:

• Diagnostic Testing: Comprehensive range of lab tests including routine blood work, health check panels, and preventive screenings.

• Home Sample Collection: Hassle-free sample collection directly from patients’ homes, saving time and reducing the inconvenience of travel and waiting times.

• Teleconsultation: Seamless video consultations with qualified doctors for timely advice, follow-ups, and management of chronic conditions.

• Digital Access: Easy access to lab reports, prescriptions, and doctor consultations via a user-friendly website and mobile app.

•  

India’s diagnostics market, currently valued at ₹1.11 lakh crore and growing at a CAGR of 14%, is witnessing a rapid shift towards home-based services. Home sample collection alone is expected to contribute 25–30% of this market in the coming year. Aayush Wellness Limited aims to capitalize on this growing demand by offering a fully integrated platform that simplifies the entire healthcare journey—from scheduling tests to receiving medical advice—while maintaining affordability and reliability.

“In today’s fragmented healthcare system, even basic services like diagnostic tests or follow-up consultations often involve unnecessary delays and high costs,” said Mr. Naveena Kumar, Managing Director of Aayush Wellness Limited. “Our goal is to bring simplicity and trust to every household, where booking a test or consulting a doctor is as easy as ordering groceries online. This is not just a business expansion—it’s a step towards reshaping everyday healthcare for millions.”

With its new verticals, Aayush Wellness Limited is building a holistic ecosystem that supports preventive care at every stage, empowering individuals to proactively manage their health. This model particularly benefits chronic disease patients, seniors requiring regular monitoring, and working individuals who struggle to prioritize routine healthcare. By integrating wellness products, nutraceuticals, herbal solutions, and now diagnostics under one umbrella, the company strengthens its diversified business model, ensuring long-term stability and growth.

Emcure Pharmaceuticals announced on Saturday that it will acquire the remaining 20.42% stake in its subsidiary Zuventus Healthcare Ltd from minority shareholders for a total consideration of ₹724.9 crore.

In a regulatory filing, the company stated that its Board of Directors has approved the proposal to enter into agreements with Zuventus’ minority shareholders to acquire their remaining shareholding. Upon completion of the transaction, Zuventus Healthcare will become a wholly owned subsidiary of Emcure Pharmaceuticals.

The acquisition will be executed through cash payments amounting to ₹724.9 crore, which will be made in one or more tranches at the time of closing, based on the agreed valuation. Currently, Emcure holds a 79.58% stake in Zuventus Healthcare.

The transaction is expected to be finalized during the September quarter of the financial year 2025-26.

Emphasizing the strategic importance of the domestic market, Emcure Pharmaceuticals said that this move will allow full financial consolidation of Zuventus, enhance alignment across its domestic business operations, and unlock significant synergies. The company believes that this acquisition will contribute to long-term value creation for Emcure.

In a landmark move to transform the National Health Service (NHS), the UK government has announced plans to sequence the entire genome of every newborn within the next decade. This ambitious initiative is part of a sweeping 10-year strategy aimed at shifting healthcare from treating illness to predicting and preventing it.

Health Secretary Wes Streeting emphasized that advancements in genomics could enable early identification of disease risks, allowing for personalized interventions long before symptoms emerge. “This revolution in medical science allows us to transform the NHS into a service that predicts and prevents illness, rather than simply diagnosing and treating it,” Streeting said. “Genomics gives us the opportunity to stay one step ahead of disease, offering personalized care that reduces strain on NHS services and helps people lead longer, healthier lives.”

The new plan, to be officially unveiled next month, proposes routine whole genome sequencing for all newborns. This would replace the current standard heel-prick blood test, which screens for just nine rare conditions. Instead, samples — often collected from the umbilical cord — would be analyzed for hundreds of genetic disorders, dramatically expanding early detection capabilities.

Backed by a £650 million investment in genomics as part of the government’s broader Life Sciences strategy, the initiative builds on successful pilot programs that sequenced 100,000 newborn genomes. Similar efforts in countries like Japan have inspired the UK’s bold approach.

Beyond newborn screening, the 10-year strategy outlines three key shifts for the NHS: moving care from hospitals into communities, transitioning from analogue to digital systems, and prioritizing disease prevention over treatment. The broader digital transformation includes innovations like smartwatch-based patient monitoring, virtual "Uber-style" hospitals connecting patients directly with specialists, and increased partnerships with private providers.

Officials believe predictive care could revolutionize medicine by enabling earlier, more targeted treatments, minimizing adverse drug reactions, and even allowing preventive prescriptions tailored to each individual’s genetic makeup. Improvements to maternity care and attention to social determinants of health, such as housing quality, are also expected to be addressed.

However, the proposal raises ethical and privacy concerns. Parents would need to consent to genomic testing, but some worry about the psychological impact of knowing their child’s genetic predispositions to conditions such as Alzheimer’s or aggressive cancers. For instance, a recent study of 7,000 infants identified 27 carrying the BRCA1 gene mutation, which is linked to a significantly higher risk of breast cancer.

Data security also remains a concern. The genetic information will be stored in the National Genomic Research Library, with identifying details encrypted and separated to protect privacy. Yet, the threat of cyberattacks persists; in 2023, genetic testing company 23andMe faced a £2.3 million fine after a data breach exposed UK user information.

Despite these risks, officials maintain that strong safeguards will ensure the benefits far outweigh potential downsides. “Healthcare must evolve alongside scientific advancements,” one source stated. “This is about giving every child the best possible start and promoting lifelong health.”

Meril Life Sciences has introduced MyClip, India’s first Transcatheter Edge-to-Edge Repair (TEER) system, on June 14. The launch event, held at Meril Academy in Vapi (Gujarat), gathered over 150 interventional cardiologists and cardiac imaging specialists from across India for the Structural Heart Innovation event.

Currently recognized as a global leader in TAVI (Transcatheter Aortic Valve Implantation) with its Myval THV platform, Meril becomes the first Indian company to launch a TEER system. This positions India prominently on the global map of transcatheter heart valve therapies, which include both replacement and repair technologies. The introduction of MyClip highlights India’s expanding capabilities in structural heart interventions and reflects Meril’s ongoing dedication to delivering cutting-edge and accessible cardiac care solutions.

The MyClip TEER System is particularly suited for patients with severe Mitral Regurgitation (MR) who are at elevated surgical risk due to conditions such as hypertension, diabetes, obesity, advanced age, frailty, enlarged or weakened hearts, and complications related to kidney, lung, or liver disease. Without timely intervention, MR can have a devastating prognosis—over 50% of untreated patients may not survive, with one-year mortality rates reaching as high as 57%.

MyClip offers precise closure of the mitral valve leaflets, effectively preventing the backward leakage of blood into the lungs. The minimally invasive procedure typically takes about one hour, allowing patients to return home within 3–5 days. After discharge, most patients can resume daily activities like walking and light work within a short recovery period.

The system’s clinical benefit is supported by data from the landmark COAPT trial, published in the New England Journal of Medicine (NEJM). In this study, patients undergoing device-based mitral repair showed substantially better outcomes than those receiving only standard medical therapy. Over 24 months, hospitalizations for heart failure decreased to 35.8% per patient-year in the device group, compared to 67.9% in the control group. Mortality was also significantly lower: 29.1% in the device group versus 46.1% in the control group.

Currently, around 150 TEER procedures are performed annually in India, mostly in younger patients aged 30–60 years, highlighting an urgent need for early interventions in this demographic.

The introduction of MyClip marks a transformative milestone for structural heart care in India. TEER therapy has demonstrated clear advantages over conventional Guideline Directed Medical Therapy (GDMT) and signals a major advancement in India’s cardiovascular treatment landscape.

In his address, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, shared that approximately 1.5 million people in India are estimated to suffer from severe mitral regurgitation, with at least 1.2 million developing MR after myocardial infarction or heart failure. The launch of MyClip represents a pivotal shift towards early adoption of TEER therapy. Bhatt emphasized the importance of Meril’s initiatives in training cardiologists and advancing TEE-based imaging, which are key to expanding this life-saving technology nationwide.

Bhatt further stated:
"With MyClip, Meril is redefining India’s place in the global medtech arena. This indigenous innovation showcases the power of collaboration across Indian science, engineering, and clinical practice. Our national public awareness campaign, #TreatmentZarooriHai, fronted by brand ambassador MS Dhoni, is actively educating patients and families about the critical importance of timely intervention in mitral valve regurgitation."

The two-day Structural Heart Innovation conference featured live case demonstrations, interactive workshops, and lectures by leading interventional cardiologists and echocardiologists. The event concluded with a strong call to build a robust M-TEER ecosystem in India, focused on accessibility, clinical excellence, and ongoing innovation.

Sequel Med Tech announced at the American Diabetes Association’s 85th Scientific Sessions in Chicago that it is preparing to launch its twiist system in July. Dr. Joanna Mitri, Sequel’s Chief Medical Officer, provided the update during a Product Theater session at the ADA event, stating that the automated insulin delivery system is scheduled for launch on July 7. This marks a slight delay from the company’s earlier projection in March, when it anticipated a second-quarter rollout.

The twiist system is built upon proprietary drug delivery technology developed by DEKA R&D. Dean Kamen, co-founder of Sequel and founder of DEKA, who previously pioneered the first wearable insulin pump, described twiist as the “next generation of insulin delivery” when discussing the system last year. Sequel secured FDA clearance for twiist in March 2024.

At the core of the twiist system is its integration with the twiist Loop algorithm, which enables precise measurement of insulin volume delivered with each microdose. Utilizing sound wave technology, the system accurately monitors every pulse of insulin, enhancing dosing precision and offering detailed insight into the exact amount of insulin administered per dose. This level of precision supports highly individualized dosing tailored to each patient’s specific needs.

The twiist system incorporates Sequel’s iiSure technology, featuring four safety checkpoints that ensure accurate insulin delivery and rapidly notify users of any blockages. The system is FDA-cleared for individuals aged six and older with type 1 diabetes, providing a more personalized and responsive approach to diabetes management.

In March, Sequel also announced a partnership with Abbott to integrate Abbott’s Libre continuous glucose monitor (CGM) as the first CGM platform compatible with twiist. Additionally, the company has reached agreements to integrate the system with Abbott’s forthcoming dual glucose-ketone sensor and with Senseonics’ Eversense 365, a year-long implantable CGM, broadening the system’s connectivity and enhancing patient monitoring options.

S.L. Raheja Hospital, a Fortis Associate in Mumbai, has unveiled a range of advanced medical services, reinforcing its position at the forefront of healthcare excellence. The hospital has launched AI-enabled Digital Positron Emission Tomography-Computed Tomography (Digital PET CT) and 3 Tesla Magnetic Resonance Imaging (3T-MRI) facilities, marking a significant leap forward in precision diagnostics.

The newly introduced Digital PET CT system—only the second of its kind in Mumbai—delivers superior image resolution and faster scan times, while embedded AI technology enhances diagnostic accuracy and patient comfort. Alongside this, the 3 Tesla MRI system offers highly detailed, high-resolution imaging with expedited scan durations, improving diagnostic precision and patient throughput.

In addition to these diagnostic advancements, S.L. Raheja Hospital has expanded its pediatric services by inaugurating cutting-edge Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU) facilities. Designed to cater to the comprehensive medical and emotional needs of young patients and their families, these units integrate advanced technology with compassionate care, ensuring timely, specialized, and holistic treatment for critically ill infants and children.

The unveiling ceremony, attended by Trustee Mr. C.L. Raheja and other dignitaries, marks a milestone in the hospital's ongoing commitment to delivering world-class healthcare services in Mumbai.

In a landmark achievement in cardiac care, Kauvery Hospital Alwarpet successfully saved the life of a 62-year-old man suffering from a severe cardiac arrest, using an advanced life-saving procedure known as ECMO-CPR (Extracorporeal Cardiopulmonary Resuscitation), a highly specialized intervention rarely deployed in critical cardiac emergencies.

The patient arrived at the Emergency Department with a major anterior wall myocardial infarction, already in cardiogenic shock—a state where the heart is unable to pump sufficient blood, leading to dangerously low blood pressure and impaired organ perfusion. While being rushed to the Cath Lab for an emergency angioplasty, he experienced complete cardiorespiratory arrest. Conventional CPR failed to revive spontaneous circulation, placing him in refractory cardiac arrest—a condition where survival is extremely rare without advanced circulatory support.

Recognizing the critical situation, a multidisciplinary team led by Dr. R. Anantharaman and Dr. S. Srikumar promptly initiated ECMO-CPR. Blood was withdrawn through cannulation of the femoral vein, oxygenated via an external membrane (oxygenator), and returned to the body through the femoral artery. This external circuit ensured continuous oxygen delivery and organ perfusion, allowing doctors the crucial time needed to address the blocked coronary arteries. A high-risk multivessel angioplasty and stenting procedure was successfully performed even as the patient’s heart remained non-functional.

Post-procedure, the patient was moved to the Coronary Care Unit (CCU) on ECMO support and subsequently transitioned to Intra-Aortic Balloon Pump (IABP) support. However, complications arose when he developed a ventricular tachycardia (VT) storm—an aggressive, life-threatening arrhythmia. Initial medical management was followed by a radiofrequency ablation, performed by the electrophysiology team led by Dr. Deep Chandh Raja, which successfully stabilized his heart rhythm.

“Survival rates for sudden cardiac arrest after myocardial infarction are less than 15% with standard CPR,” noted Dr. S. Srikumar. “The timely use of ECMO-CPR significantly improves survival, potentially doubling these odds.”

Dr. Aravindan Selvaraj, Co-Founder and Executive Director, emphasized that such outcomes are possible only with rapid decision-making, expert multidisciplinary coordination, advanced technology, and round-the-clock critical care support.

After 21 days of intensive treatment, the patient was discharged fully mobile and neurologically intact—an inspiring testament to the power of advanced cardiac care.

Starting June 30, eligible residents in Singapore will have access to government-subsidized genetic testing for familial hypercholesterolemia (FH), a hereditary condition that leads to elevated cholesterol levels. This initiative forms part of the country’s broader Healthier SG strategy, which focuses on preventive healthcare and early intervention.

According to the Ministry of Health, the new program aims to detect FH early and reduce the risk of premature heart disease through timely diagnosis and management. FH is a genetic disorder that hampers the body’s ability to regulate cholesterol, affecting around 20,000 people in Singapore. Individuals with FH face up to a 20-fold higher risk of experiencing heart attacks at a younger age compared to the general population.

In a statement posted on Facebook, Health Minister Ong Ye Kung emphasized the government’s long-term vision to incorporate predictive preventive care into national health policies. “This is part of our broader effort to expand predictive preventive care under Healthier SG,” he noted, adding that there are plans to extend genetic testing to other conditions in the future.

Primary care providers, including general practitioners and polyclinics, will play a key role in identifying individuals who may have FH. Those suspected of having the condition, along with their immediate family members — parents, children, and siblings — will be referred for genetic screening. Individuals who test positive will receive personalized preventive care recommendations aimed at managing their cardiovascular risk.

The cost of genetic testing will be subsidized by the government. Additionally, eligible residents may tap into their MediSave accounts — Singapore’s national medical savings scheme — to help cover associated healthcare expenses, such as hospital stays, surgeries, and specific outpatient treatments.

This initiative marks a significant step in Singapore’s efforts to leverage precision medicine and genetic screening to improve public health outcomes through early detection and preventive care.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending marketing authorisation for darolutamide, in combination with androgen deprivation therapy (ADT), for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union. This recommendation, announced by Orion’s partner Bayer, is based on results from the pivotal Phase III ARANOTE trial.

The ARANOTE study demonstrated that adding darolutamide to ADT significantly lowered the risk of radiological progression or death by 46% compared to placebo plus ADT (Hazard Ratio 0.54; 95% CI 0.41–0.71; P<0.0001). The European Commission is expected to make a final decision on the marketing authorisation in the coming months.

If approved, this expanded indication would offer physicians greater flexibility to individualize treatment plans, allowing the use of darolutamide plus ADT with or without chemotherapy (docetaxel) based on individual patient needs.

Darolutamide, an oral androgen receptor inhibitor (ARi), is already approved in more than 85 countries under the brand name Nubeqa®. In June 2025, the U.S. Food and Drug Administration (FDA) approved darolutamide in combination with ADT for mHSPC, with or without chemotherapy, making it the first and only ARi with this approval in the United States. It is also approved in combination with ADT and docetaxel for mHSPC and as monotherapy with ADT in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients at high risk of disease progression.

Prostate cancer remains a major global health concern, ranking as the second most common cancer and the fifth leading cause of cancer-related deaths among men worldwide. In 2022, approximately 1.5 million men were newly diagnosed with prostate cancer, with nearly 397,000 deaths reported globally. In Europe alone, around 474,000 new cases and 115,000 deaths were estimated in 2022. Projections suggest prostate cancer diagnoses could rise to 2.9 million by 2040.

The positive CHMP opinion represents a significant step forward in expanding treatment options for patients with advanced prostate cancer in Europe.

Bajaj Allianz General Insurance, one of India’s leading private insurers, has introduced an innovative health insurance product — the ‘State-wise Health Insurance Policy’. This first-of-its-kind offering is designed to address the distinct healthcare needs, treatment availability, and medical costs that vary significantly across India’s diverse states and union territories.

Unlike conventional one-size-fits-all policies, this new product takes a highly localised approach, customising coverage based on each state’s unique healthcare ecosystem. Bajaj Allianz has carefully factored in local hospital infrastructure, prevalent diseases, medical inflation, and affordability to design policies that are both relevant and practical for residents in each region.

The State-wise Health Insurance Policy offers comprehensive protection with flexible sum insured options ranging from INR 5 lakh to INR 20 lakh. It is available in both individual and floater variants, catering to a wide spectrum of customers — from young professionals to senior citizens. Key benefits include coverage for inpatient hospitalisation, pre- and post-hospitalisation expenses, day care procedures, and advanced treatments such as robotic surgeries and stem cell therapy. Additionally, organ donor expenses are included in the base policy, providing crucial financial support for transplant procedures.

To ensure uninterrupted protection, the policy offers lifetime renewability without any age restrictions. Optional features further enhance coverage: Unlimited Sum Insured Reinstatement allows policyholders to restore their sum insured multiple times within a policy year, while the Super Cumulative Bonus rewards claim-free years with up to 200% additional sum insured. For customers opting for cashless claims, a Cashless Discount reduces premiums, making the policy more economical. An Accidental Death Cover adds another layer of financial security for families.

In a unique touch, Bajaj Allianz has branded these policies with names inspired by local languages and cultures to better resonate with customers. For instance, in Hindi-speaking states, the product is called “AapKe Liye”. The policies have been launched across 25 states and 5 Union Territories, each tailored to the specific healthcare needs of the region.

Dr. Tapan Singhel, MD & CEO of Bajaj Allianz General Insurance, stated, “India’s diversity calls for equally diverse healthcare solutions. This initiative ensures that health insurance is not just available but relevant and affordable for every Indian.”

To further encourage healthy living, the policy offers wellness discounts at renewal — a 5% premium discount for achieving 7,500 steps daily and a 10% discount for 10,000 steps over at least 9 months. A Festive Bonus also provides an additional INR 1,000 per day for hospitalisation during festivals.

The policies can be purchased through the company’s wide distribution network, including branches, agents, partner banks, digital platforms, and the ‘Caringly Yours’ mobile app. This launch marks a significant shift toward personalised, accessible, and inclusive health insurance across India.